X4 Pharmaceuticals, Inc. (XFOR) Investor Relations Documents

X4 Pharmaceuticals, Inc. (XFOR) investor relations documents from the company's IR site: 18 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releasePDF Version
2026-08-06Press releaseX4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-03Press releasePDF Version
2026-08-03Press releaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-07Press releaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01Press releaseX4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
2026-06-01Press releaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-27Press releaseX4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-06Press releaseX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-04-29Press releaseX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Trea
2026-04-01Press releaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-17Press releaseX4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-03-04Press releaseX4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
2026-03-02Press releaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-27Press releaseX4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM S
2026-02-03Press releaseX4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
2026-02-02Press releaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseX4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

XFOR overview · XFOR earnings · XFOR financials · XFOR KPIs · XFOR ownership · XFOR peers · XFOR filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.